This 271-page report from TriMark Publications provides a comprehensive overview of the breast cancer therapies market. It details the major drug classes used to treat breast cancer, including chemotherapy, hormone therapy, targeted therapies, and drugs in development. The report examines key factors shaping the market such as regulatory trends, reimbursement, companion diagnostics, and the impact of generics. It also provides global and regional breast cancer statistics and discusses the seven main treatment modalities. Major topics covered include game-changing drugs for HER2-positive and estrogen receptor-positive breast cancer, as well as triple negative breast cancer.
El documento describe el sistema nacional de salud peruano. Este sistema está compuesto por el sector público (incluyendo el MINSA y EsSalud) y el sector privado. El MINSA es la institución encargada de velar por la salud de la población y promover la participación multisectorial. El sistema se organiza en tres niveles de atención - primer nivel en centros de salud comunitarios, segundo nivel en hospitales regionales, y tercer nivel en hospitales especializados.
El documento describe la estructura del sistema de salud venezolano. Se compone de tres niveles de atención: primaria, secundaria y terciaria. El primer nivel incluye ambulatorios rurales y urbanos tipo I y II, y cubre el 80-85% de la población. El segundo nivel incluye hospitales tipo I y II, ambulatorios urbanos tipo III y parte del primer nivel. El tercer nivel comprende hospitales tipo III y IV y cubre solo el 5% de la población con atención altamente especializada.
La epicrisis es el resumen de la enfermedad y proceso médico de un paciente que se confecciona al darle de alta o derivarlo a otro profesional. Tiene utilidad para el paciente, médicos tratantes, sistema de salud y hospital, ya que permite realizar estadísticas, evaluaciones, contabilizar acciones médicas, docencia, investigación y auditorías. Debe contener datos del paciente, diagnósticos, tratamientos, condición de egreso y estar escrita de forma legible, completa y útil.
Este documento proporciona una guía de 11 puntos para realizar evoluciones médicas de manera efectiva. Las evoluciones deben ser legibles, breves, completas y útiles, registrando signos vitales, diagnósticos, tratamientos, resultados de exámenes, consultas y opiniones recibidas. También deben incluir detalles relevantes sobre el paciente como adherencia al tratamiento, y demoras o problemas en la atención recibida. El jefe de sala debe realizar un balance y plan de acción cuando sea apropiado.
Este documento presenta varias métricas para medir la productividad de un hospital, incluyendo el número de camas disponibles y en uso, días de hospitalización, promedio de censo diario, tasa de admisión, promedio de estancia, y porcentaje de ocupación. Calcula estas métricas usando datos como días de hospitalización, población del área, admisiones, egresos, y días del periodo.
This 271-page report from TriMark Publications provides a comprehensive overview of the breast cancer therapies market. It details the major drug classes used to treat breast cancer, including chemotherapy, hormone therapy, targeted therapies, and drugs in development. The report examines key factors shaping the market such as regulatory trends, reimbursement, companion diagnostics, and the impact of generics. It also provides global and regional breast cancer statistics and discusses the seven main treatment modalities. Major topics covered include game-changing drugs for HER2-positive and estrogen receptor-positive breast cancer, as well as triple negative breast cancer.
El documento describe el sistema nacional de salud peruano. Este sistema está compuesto por el sector público (incluyendo el MINSA y EsSalud) y el sector privado. El MINSA es la institución encargada de velar por la salud de la población y promover la participación multisectorial. El sistema se organiza en tres niveles de atención - primer nivel en centros de salud comunitarios, segundo nivel en hospitales regionales, y tercer nivel en hospitales especializados.
El documento describe la estructura del sistema de salud venezolano. Se compone de tres niveles de atención: primaria, secundaria y terciaria. El primer nivel incluye ambulatorios rurales y urbanos tipo I y II, y cubre el 80-85% de la población. El segundo nivel incluye hospitales tipo I y II, ambulatorios urbanos tipo III y parte del primer nivel. El tercer nivel comprende hospitales tipo III y IV y cubre solo el 5% de la población con atención altamente especializada.
La epicrisis es el resumen de la enfermedad y proceso médico de un paciente que se confecciona al darle de alta o derivarlo a otro profesional. Tiene utilidad para el paciente, médicos tratantes, sistema de salud y hospital, ya que permite realizar estadísticas, evaluaciones, contabilizar acciones médicas, docencia, investigación y auditorías. Debe contener datos del paciente, diagnósticos, tratamientos, condición de egreso y estar escrita de forma legible, completa y útil.
Este documento proporciona una guía de 11 puntos para realizar evoluciones médicas de manera efectiva. Las evoluciones deben ser legibles, breves, completas y útiles, registrando signos vitales, diagnósticos, tratamientos, resultados de exámenes, consultas y opiniones recibidas. También deben incluir detalles relevantes sobre el paciente como adherencia al tratamiento, y demoras o problemas en la atención recibida. El jefe de sala debe realizar un balance y plan de acción cuando sea apropiado.
Este documento presenta varias métricas para medir la productividad de un hospital, incluyendo el número de camas disponibles y en uso, días de hospitalización, promedio de censo diario, tasa de admisión, promedio de estancia, y porcentaje de ocupación. Calcula estas métricas usando datos como días de hospitalización, población del área, admisiones, egresos, y días del periodo.
Este documento discute la profilaxis antibiótica en cirugía. Explica que las infecciones de herida quirúrgica (IHQ) son comunes y costosas, y que la profilaxis antibiótica puede reducir el riesgo de IHQ al eliminar bacterias introducidas durante la cirugía. Detalla factores de riesgo para IHQ como el estado del paciente, tipo de cirugía y microorganismos involucrados. Recomienda el uso de cefalosporinas de primera generación como cefazolina para la mayoría de cirugías, con dosis
El documento describe varios indicadores hospitalarios importantes como consultas nuevas, camas disponibles, pacientes-día, tasas de ocupación, mortalidad y giro de camas. Explica cómo calcular cada indicador y qué información proporcionan sobre el volumen de pacientes, uso de recursos y resultados en un hospital.
El documento habla sobre indicadores hospitalarios. Define conceptos como ingreso hospitalario, egreso hospitalario, cama disponible, días cama ocupada y estancia. Explica cómo calcular indicadores como porcentaje ocupacional, promedio día-estancia y giro de camas. Finalmente, da datos para calcular e interpretar estos indicadores.
Este documento proporciona información sobre la historia clínica. Define la historia clínica y explica sus funciones médico-legales, de gestión, docencia e investigación. Detalla los diferentes tipos de historia clínica, sus partes y la información que debe incluir cada parte como los datos de filiación, antecedentes personales y familiares.
Este documento describe los indicadores de salud y su importancia. Los indicadores son medidas resumen que facilitan la evaluación de la situación sanitaria de una población o el desempeño de un sistema de salud. Pueden medir la estructura, los procesos o los resultados y son útiles para el análisis, la toma de decisiones, la planificación y la programación en salud. Algunos ejemplos son tasas de mortalidad, porcentajes de ocupación hospitalaria y proporciones de consultas iniciales.
Este documento define la historia clínica y sus partes principales. Explica que la historia clínica es un instrumento médico y jurídico que recopila datos sobre un paciente para fundamentar el diagnóstico, pronóstico y tratamiento. Sus partes clave son la anamnesis, examen físico, diagnóstico, tratamiento y evolución. Además, describe formatos especiales como notas de enfermería, hoja de control de medicamentos, informes quirúrgicos e informes de laboratorio.
Cancer Disparities in the 21st Century - Otis W. Brawley, M.D.bkling
Otis W. Brawley gave a presentation on the evolution of our concept of cancer and disparities in cancer outcomes. Some key points:
- Our understanding of cancer has advanced from the 19th century definition to incorporating genomics and personalized medicine. Screening and diagnostic tools have also improved greatly over time.
- However, an estimated 10-20% of cancers detected through screening are overdiagnosed and do not need treatment. Screening also has harms like unnecessary biopsies and treatments.
- Disparities exist in cancer outcomes based on factors like race, income, education level, geography. An estimated 152,000 cancer deaths per year could be prevented in the US if all Americans
This chart pack provides facts and figures about prescription medicines and their role in the health care system. Topics include medicines’ impact on health and quality of life, the drug discovery and development process, biopharmaceutical spending and costs, the challenge of treatment gaps and lack of adherence to prescribed therapies, the marketing and promotion of medicines, and the role of the biopharmaceutical sector in the U.S. economy.
Data and information found in this publication were drawn from a wide range of sources, including government-agency reports, peer-reviewed journals, and the Pharmaceutical Research and Manufacturers of America’s (PhRMA’s) own research and analysis. PhRMA hopes this publication provides useful context for discussions about the role of medicines in the U.S. health care system.
This document discusses care of cancer survivors and outlines the following key points in 3 sentences:
1) Approximately 3% of the population are cancer survivors, with many being elderly and having multiple comorbidities. 2) Both cancer-related and general medical needs must be addressed in cancer survivors, including surveillance for recurrence, late effects of treatment, and new primary cancers as well as screening and management of comorbidities. 3) The role of primary care physicians in providing ongoing care for cancer survivors along with survivorship care plans is reviewed.
This document discusses the epidemiology of cancer globally and in Nepal. Some key points:
- Cancer is a leading cause of death worldwide, responsible for 1 in 8 deaths. Incidence and mortality are increasing, especially in developing countries.
- Major risk factors for cancer include tobacco use, chronic infections, alcohol, diet, obesity, radiation, and genetic factors.
- In Nepal, the most common cancers are lung, oral, stomach, and cervical cancers. The highest burden is in the BPKIHS region.
- Prevention strategies include reducing exposure to risk factors, screening programs, and early detection and treatment. Molecular epidemiology uses biomarkers to better understand cancer causes and prognosis.
Germany faces challenges from an aging population and increasing rates of non-communicable diseases. Strategies to address this include expanding long-term care options, training more geriatric specialists, promoting lifelong learning and deferred retirement, strengthening prevention of infectious diseases, and shifting to individualized and multi-cause approaches in medicine. However, implementing personalized healthcare poses cost challenges that require country-specific solutions.
1) Childhood cancer survivors face significant long-term health issues due to their prior treatments, including cognitive dysfunction, cardiac complications, growth impairment, and second cancers.
2) Survivors of hematopoietic cell transplantation also experience numerous late effects involving vital organs, endocrine and metabolic dysfunction, osteonecrosis, and secondary malignancies.
3) Close long-term follow-up is needed to monitor survivors for late complications and improve health outcomes through early detection and intervention.
Presentation by our Keynote Speaker, Leslie J. Kohman, MD at our Cancer Mission 2020 28th Congressional District Summit in Buffalo, NY. Dr. Kohman is the Professor of Surgery Medical Director at Upstate Cancer Center in Syracuse, NY.
Cancer is caused by abnormal cell growth that spreads uncontrollably. It develops through a complex interaction between genes, environment, and chance. Cancer cells do not die like normal cells and continue growing and dividing in a disorderly fashion. The media needs to accurately report on cancer research studies and not oversimplify results or mislead the public. The UK has higher cancer death rates than some other countries, which may be partly due to lower spending on cancer medications.
This document outlines a presentation on developing workplace wellness programs. It discusses how wellness programs can save companies real money by reducing healthcare costs associated with preventable conditions. The presentation provides a roadmap for launching or improving a wellness program, covering topics like the needs for wellness, benefits of worksite programs, milestones in health issues, and individual and societal behavior changes needed. Case studies are presented showing wellness programs can achieve savings-to-cost ratios of $3-$10 for every $1 invested through reduced absenteeism, healthcare costs, and other expenses.
This presentation provides an overview of cancer and therapeutics. It discusses key areas that will be covered, including cell and molecular biology of cancer development, genetic pathways, cancer diagnosis and pathology, principles of cancer chemotherapy, drug discovery and delivery, and the future of cancer research. Recent papers and discussions are also mentioned.
The rise of oral oncology drugs provides convenience for patients but also challenges for manufacturers. While oral drugs allow patients to receive treatment at home, they can lead to poor drug adherence and side effect management if taken without supervision. Additionally, different reimbursement models for oral drugs often burden patients with high out-of-pocket costs, causing some to abandon treatment prematurely. Manufacturers must address issues like adherence, side effects, off-label use, pricing and reimbursement to maximize the benefits of oral oncology drugs for patients.
DR ARYA LUNG CANCER SCREENING 28 TH JAN.pptxdranimesharya
This document summarizes guidelines for managing lung nodules found on CT scans from the British Thoracic Society and Fleischner Society. It discusses key points like who should be screened, thresholds for follow up of solid and subsolid nodules based on size, the definition of nodule growth, and duration of follow up for stable nodules. It also notes that lung cancer prevalence is similar for nodules found on screening vs incidentally. New evidence is presented on outcomes for nodules detected by screening vs incidentally managed pathways.
This document discusses the history and adoption of intensity-modulated radiation therapy (IMRT). It notes that IMRT was proposed over 40 years ago but was not widely implemented until the 1990s with the availability of commercial treatment planning systems. Two surveys from 2002 and 2004 found that adoption of IMRT in the United States grew rapidly, from 32% to 74% of radiation oncologists using it. While commonly available now, most centers only use IMRT to treat a subset of patients. The document reviews the types of cancer most commonly treated with IMRT and radiation oncologists' impressions of its effects.
Este documento discute la profilaxis antibiótica en cirugía. Explica que las infecciones de herida quirúrgica (IHQ) son comunes y costosas, y que la profilaxis antibiótica puede reducir el riesgo de IHQ al eliminar bacterias introducidas durante la cirugía. Detalla factores de riesgo para IHQ como el estado del paciente, tipo de cirugía y microorganismos involucrados. Recomienda el uso de cefalosporinas de primera generación como cefazolina para la mayoría de cirugías, con dosis
El documento describe varios indicadores hospitalarios importantes como consultas nuevas, camas disponibles, pacientes-día, tasas de ocupación, mortalidad y giro de camas. Explica cómo calcular cada indicador y qué información proporcionan sobre el volumen de pacientes, uso de recursos y resultados en un hospital.
El documento habla sobre indicadores hospitalarios. Define conceptos como ingreso hospitalario, egreso hospitalario, cama disponible, días cama ocupada y estancia. Explica cómo calcular indicadores como porcentaje ocupacional, promedio día-estancia y giro de camas. Finalmente, da datos para calcular e interpretar estos indicadores.
Este documento proporciona información sobre la historia clínica. Define la historia clínica y explica sus funciones médico-legales, de gestión, docencia e investigación. Detalla los diferentes tipos de historia clínica, sus partes y la información que debe incluir cada parte como los datos de filiación, antecedentes personales y familiares.
Este documento describe los indicadores de salud y su importancia. Los indicadores son medidas resumen que facilitan la evaluación de la situación sanitaria de una población o el desempeño de un sistema de salud. Pueden medir la estructura, los procesos o los resultados y son útiles para el análisis, la toma de decisiones, la planificación y la programación en salud. Algunos ejemplos son tasas de mortalidad, porcentajes de ocupación hospitalaria y proporciones de consultas iniciales.
Este documento define la historia clínica y sus partes principales. Explica que la historia clínica es un instrumento médico y jurídico que recopila datos sobre un paciente para fundamentar el diagnóstico, pronóstico y tratamiento. Sus partes clave son la anamnesis, examen físico, diagnóstico, tratamiento y evolución. Además, describe formatos especiales como notas de enfermería, hoja de control de medicamentos, informes quirúrgicos e informes de laboratorio.
Cancer Disparities in the 21st Century - Otis W. Brawley, M.D.bkling
Otis W. Brawley gave a presentation on the evolution of our concept of cancer and disparities in cancer outcomes. Some key points:
- Our understanding of cancer has advanced from the 19th century definition to incorporating genomics and personalized medicine. Screening and diagnostic tools have also improved greatly over time.
- However, an estimated 10-20% of cancers detected through screening are overdiagnosed and do not need treatment. Screening also has harms like unnecessary biopsies and treatments.
- Disparities exist in cancer outcomes based on factors like race, income, education level, geography. An estimated 152,000 cancer deaths per year could be prevented in the US if all Americans
This chart pack provides facts and figures about prescription medicines and their role in the health care system. Topics include medicines’ impact on health and quality of life, the drug discovery and development process, biopharmaceutical spending and costs, the challenge of treatment gaps and lack of adherence to prescribed therapies, the marketing and promotion of medicines, and the role of the biopharmaceutical sector in the U.S. economy.
Data and information found in this publication were drawn from a wide range of sources, including government-agency reports, peer-reviewed journals, and the Pharmaceutical Research and Manufacturers of America’s (PhRMA’s) own research and analysis. PhRMA hopes this publication provides useful context for discussions about the role of medicines in the U.S. health care system.
This document discusses care of cancer survivors and outlines the following key points in 3 sentences:
1) Approximately 3% of the population are cancer survivors, with many being elderly and having multiple comorbidities. 2) Both cancer-related and general medical needs must be addressed in cancer survivors, including surveillance for recurrence, late effects of treatment, and new primary cancers as well as screening and management of comorbidities. 3) The role of primary care physicians in providing ongoing care for cancer survivors along with survivorship care plans is reviewed.
This document discusses the epidemiology of cancer globally and in Nepal. Some key points:
- Cancer is a leading cause of death worldwide, responsible for 1 in 8 deaths. Incidence and mortality are increasing, especially in developing countries.
- Major risk factors for cancer include tobacco use, chronic infections, alcohol, diet, obesity, radiation, and genetic factors.
- In Nepal, the most common cancers are lung, oral, stomach, and cervical cancers. The highest burden is in the BPKIHS region.
- Prevention strategies include reducing exposure to risk factors, screening programs, and early detection and treatment. Molecular epidemiology uses biomarkers to better understand cancer causes and prognosis.
Germany faces challenges from an aging population and increasing rates of non-communicable diseases. Strategies to address this include expanding long-term care options, training more geriatric specialists, promoting lifelong learning and deferred retirement, strengthening prevention of infectious diseases, and shifting to individualized and multi-cause approaches in medicine. However, implementing personalized healthcare poses cost challenges that require country-specific solutions.
1) Childhood cancer survivors face significant long-term health issues due to their prior treatments, including cognitive dysfunction, cardiac complications, growth impairment, and second cancers.
2) Survivors of hematopoietic cell transplantation also experience numerous late effects involving vital organs, endocrine and metabolic dysfunction, osteonecrosis, and secondary malignancies.
3) Close long-term follow-up is needed to monitor survivors for late complications and improve health outcomes through early detection and intervention.
Presentation by our Keynote Speaker, Leslie J. Kohman, MD at our Cancer Mission 2020 28th Congressional District Summit in Buffalo, NY. Dr. Kohman is the Professor of Surgery Medical Director at Upstate Cancer Center in Syracuse, NY.
Cancer is caused by abnormal cell growth that spreads uncontrollably. It develops through a complex interaction between genes, environment, and chance. Cancer cells do not die like normal cells and continue growing and dividing in a disorderly fashion. The media needs to accurately report on cancer research studies and not oversimplify results or mislead the public. The UK has higher cancer death rates than some other countries, which may be partly due to lower spending on cancer medications.
This document outlines a presentation on developing workplace wellness programs. It discusses how wellness programs can save companies real money by reducing healthcare costs associated with preventable conditions. The presentation provides a roadmap for launching or improving a wellness program, covering topics like the needs for wellness, benefits of worksite programs, milestones in health issues, and individual and societal behavior changes needed. Case studies are presented showing wellness programs can achieve savings-to-cost ratios of $3-$10 for every $1 invested through reduced absenteeism, healthcare costs, and other expenses.
This presentation provides an overview of cancer and therapeutics. It discusses key areas that will be covered, including cell and molecular biology of cancer development, genetic pathways, cancer diagnosis and pathology, principles of cancer chemotherapy, drug discovery and delivery, and the future of cancer research. Recent papers and discussions are also mentioned.
The rise of oral oncology drugs provides convenience for patients but also challenges for manufacturers. While oral drugs allow patients to receive treatment at home, they can lead to poor drug adherence and side effect management if taken without supervision. Additionally, different reimbursement models for oral drugs often burden patients with high out-of-pocket costs, causing some to abandon treatment prematurely. Manufacturers must address issues like adherence, side effects, off-label use, pricing and reimbursement to maximize the benefits of oral oncology drugs for patients.
DR ARYA LUNG CANCER SCREENING 28 TH JAN.pptxdranimesharya
This document summarizes guidelines for managing lung nodules found on CT scans from the British Thoracic Society and Fleischner Society. It discusses key points like who should be screened, thresholds for follow up of solid and subsolid nodules based on size, the definition of nodule growth, and duration of follow up for stable nodules. It also notes that lung cancer prevalence is similar for nodules found on screening vs incidentally. New evidence is presented on outcomes for nodules detected by screening vs incidentally managed pathways.
This document discusses the history and adoption of intensity-modulated radiation therapy (IMRT). It notes that IMRT was proposed over 40 years ago but was not widely implemented until the 1990s with the availability of commercial treatment planning systems. Two surveys from 2002 and 2004 found that adoption of IMRT in the United States grew rapidly, from 32% to 74% of radiation oncologists using it. While commonly available now, most centers only use IMRT to treat a subset of patients. The document reviews the types of cancer most commonly treated with IMRT and radiation oncologists' impressions of its effects.
Treatments of breast cancer in 2012: Where are we now? - Janice WalsheIrish Cancer Society
- The document discusses treatment approaches for breast cancer in 2012, including updates in diagnostics and therapies such as Oncotype DX testing, hormonal therapies, chemotherapy, and targeted therapies.
- It provides an overview of staging breast cancer and how factors like tumor size, lymph node involvement, and hormone receptor status influence treatment decisions.
- Testing such as Oncotype DX can help determine which early-stage, hormone receptor-positive, lymph node-negative breast cancer patients are likely to benefit from chemotherapy based on their recurrence score. This helps avoid unnecessary chemotherapy treatment and side effects.
How We Do Harm: A Webinar by SHARE with Dr. Otis Brawleybkling
Dr. Otis Brawley, author of How We Do Harm, pulls back the curtain on how health care is really practiced in American. Hosted by SHARE: Self-help for Women with Breast or Ovarian Cancer.. www.sharecancersupport.org. If you would like to watch the full webinar, visit www.sharecancersupport.org/brawley.
Over the past century, cancer treatment and outcomes have significantly improved due to advances in chemotherapy, radiation therapy, screening, surgery, and targeted molecular therapies. Five-year survival rates for many cancers have doubled or tripled compared to the 1970s. Recent decades have seen the development of targeted drugs, genomic mapping, and vaccines to prevent certain cancers. There are now over 13 million cancer survivors in the US, compared to just 3 million in the 1970s, demonstrating major gains against cancer.
'THE ‘UNIQUENESS’ OF CANCER' by Professor Graham Mann - Sick or Treat SessionsRareCancersAustralia
The document discusses cancer statistics in Australia and melanoma in particular. It provides key facts about cancer rates and the most common types of cancer diagnosed in Australia. It then discusses what is known about what causes cancer on a genetic level and factors that can damage genes like chemicals, radiation, and infections. The document outlines some of the approaches used to treat cancer including prevention, early detection, surgery, radiation, and newer targeted drugs and immunotherapy. It acknowledges that while treatments have improved for some cancers, more work remains to fully understand and treat cancer given its complexity.
Similar to Denjoy, Nicole - The importante of innovative technologies in healthcare. COCIR’s viewpoint (20)
The GSMA represents over 800 mobile operators and 200 associate members across 219 countries. It aims to drive growth in the mobile industry through innovation. There are already over 500 mHealth deployments worldwide, especially in Asia, Africa, and Europe. The GSMA's mission is to reduce healthcare costs and improve patient care through accelerating the deployment of scalable and interoperable mobile health solutions.
The document discusses shifting trends in mobile platforms and their implications for mHealth. It notes that smartphones have reached 50% market share in major markets and that 84% of US doctors will have smartphones by 2011. It analyzes usage and market shares of platforms like iOS, Android, Windows Phone and Blackberry. It also discusses design trends in consumer mobile apps that will influence mHealth apps and challenges of user retention for mobile apps.
This document summarizes a conference on trends in mobile health (mHealth) held on May 25, 2012 in Barcelona. The conference featured presentations from experts on mHealth trends globally and in Spain. It also included a debate on how mHealth is evolving from pilots to mainstream applications and the challenges of interoperability, scalability, and sustainability of mHealth initiatives. The floor was then opened for further debate.
The document discusses challenges facing health systems, including an aging population with multiple chronic conditions, rising costs, and technological advances. It focuses on reforms to improve coordination within and outside of hospitals to better manage chronic diseases. This includes strengthening primary care, public health interventions, and aligning payment systems to prioritize prevention and care outside of hospitals when possible. The goal is to improve outcomes and make more efficient use of resources.
Albert Laszlo Barabasi - Innovation inspired positive change in health careponencias_mihealth2012
This document summarizes network medicine and its applications. It discusses how human diseases can be modeled and studied as complex networks. Disease genes are found to cluster together in protein interaction networks, forming disease modules. Mapping disease genes onto interactome networks can help identify new candidate genes and delineate disease modules. Validation using various biological data shows the predicted disease genes are statistically associated with the disease. Mapping asthma genes in this way identified a statistically significant disease module within the first 200 prioritized genes. Network medicine approaches provide a framework for understanding the molecular basis of diseases.
Este documento describe la posibilidad de realizar tratamientos de rehabilitación en el hogar del paciente mediante el uso de videoconsolas y juegos. La telerehabilitación permite programar y controlar ejercicios de rehabilitación de forma remota para complementar los tratamientos presenciales. El proyecto Play for Health utiliza una videoconsola para diseñar juegos de rehabilitación específicos que estimulan la movilidad y cognición del paciente, permitiendo al equipo clínico realizar un seguimiento remoto.
Moya, Francesc - Mapa de Tendencias: Encuesta sobre el uso de las TIC en Salu...ponencias_mihealth2012
El documento describe la Encuesta sobre el Uso de las TIC en Salud en Cataluña. Se realiza desde 2007 para conocer el estado de las tecnologías de la información y comunicación en el sector salud de Cataluña y orientar las decisiones estratégicas. La encuesta recoge datos sobre plataformas tecnológicas, sistemas de información, tratamiento de la información clínica, conectividad e interoperabilidad, seguridad y gestión de las TIC. Los resultados se comparten con los proveedores de salud para que puedan compararse y conoc
Martinez, Elena - Escola de Salut de la Barceloneta. Un proyecto para el empo...ponencias_mihealth2012
Este documento describe el proyecto "Escola de Salut de la Barceloneta", cuyo objetivo es proporcionar más autonomía a las personas mayores e involucrar a la población en la gestión del sistema sanitario. El proyecto involucra a varias organizaciones comunitarias y ofrece talleres sobre temas de salud, nutrición y envejecimiento para empoderar a los participantes. El proyecto evalúa continuamente su organización, programa y docentes para mejorar continuamente.
Lukacs, Eloi - Exercise is Medicine: possible everywhere with mywellness keyponencias_mihealth2012
This document discusses the benefits of exercise for health and introduces the mywellness key and portal as tools for evaluating patient habits, prescribing customized exercise programs, motivating and educating patients, and remotely monitoring their progress. It also notes that physical activity levels can impact obesity rates around the world and provides contact information for the key account manager at Technogym.
El proyecto ComPENSA tuvo como objetivo principal desarrollar un modelo para reducir el consumo innecesario de antibióticos mediante intervenciones dirigidas al personal sanitario y pacientes en un área sanitaria integrada que incluye 254.000 habitantes. El proyecto implementó actividades formativas y de comunicación durante varios años y logró reducir el consumo de antibióticos en un 6%, disminuyendo la dosis diaria definida de 24,23 a 22,82 entre los períodos pre- y post-proyecto.
Escudero, Joan - Chronic disease management for Diabetes. Sucessful integrati...ponencias_mihealth2012
The document discusses integrating the private telemedicine service Medical Guard into Catalunya's public Personal Health Folder initiative. Medical Guard allows close monitoring of diabetic patients by collecting blood glucose readings via mobile devices and the internet. Integrating it into the Personal Health Folder will give diabetic citizens access to the service directly through their public health profile. This public-private partnership combines advanced private technologies with public health initiatives to improve care for chronic conditions like diabetes.
De Haro, Andreu - Proyecto e-learning aplicado en el Hospital Universitario V...ponencias_mihealth2012
El Hospital Universitario Vall d'Hebron implementó un proyecto de aprendizaje electrónico (e-learning) para mejorar la formación de su personal. Crearon una plataforma de formación en línea propia para proporcionar una oferta formativa más accesible y actualizada. La plataforma se utilizó para impartir una sesión sobre cateterización de vías periféricas a 1.240 profesionales, lo que resultó en una reducción del 56,25% de las bacteriemias asociadas y ahorros económicos de entre 126.865
Closa, Conxita - Transformación de la medicina y de los servicios sanitariosponencias_mihealth2012
La plataforma interactiva de rehabilitación propone un modelo innovador de terapia combinada que incluye tanto controles presenciales como trabajo en línea para optimizar los recursos y atender a más pacientes. El programa ofrece sesiones presenciales iniciales seguidas de sesiones en línea con controles virtuales del tutor, con el objetivo de que los pacientes adquieran progresivamente un mayor grado de conocimiento sobre su condición hasta convertirse en "pacientes expertos".
Atienza, Carlos - Experiencias empresariales en desarrollo de tecnología sani...ponencias_mihealth2012
El documento describe cómo la empresa Gasmedi pasó de ser un proveedor de servicios de terapias respiratorias a domicilio a ser también un fabricante de productos sanitarios. Con la colaboración del Instituto de Biomecánica de Valencia, Gasmedi desarrolló una nueva máscara para el tratamiento de la apnea del sueño aplicando un modelo de innovación abierta que implicó a usuarios, centros de investigación y fabricantes. El nuevo diseño de máscara mejora los problemas de usabilidad y riesgos para la salud de los modelos existentes.
Garcia, Joaquin - Tratamiento preventivo de enfermos crónicos con ayuda de la...ponencias_mihealth2012
El documento describe el proyecto Sophi@, un programa de coaching para pacientes crónicos en Francia que combina factores tecnológicos y humanos. El proyecto incluye la segmentación de pacientes, modelos predictivos, acompañamiento a través de plataformas digitales y asesores de salud, con el objetivo de mejorar la calidad de vida y ahorrar recursos sanitarios.
The document discusses using an open innovation network to manage ideas and innovation projects across multiple hospitals and provider groups. It introduces Induct Software, an innovation management platform that can help establish such a network. Induct allows hospitals to capture ideas from various stakeholders, manage innovation projects and portfolios, and facilitate collaboration both within and outside each organization through an open innovation portal. The document provides examples of how Induct has helped healthcare innovation consortiums like CIMIT to connect researchers, hospitals and funders.
Sitjar, Salvador - Proyecto sobre un nuevo modelo de autogestión profesional ...ponencias_mihealth2012
Este documento describe un proyecto de autogestión profesional en atención primaria implementado en el CAP Les Corts de Barcelona. El proyecto GAPI otorgó autonomía a los profesionales para organizar su trabajo y evaluó resultados entre 2008-2011, mostrando mejoras como una reducción del 27.7% en visitas presenciales, un aumento del 652.7% en atención no presencial, y una reducción del 9.5% en gastos de farmacia. El modelo GAPI demostró ser más eficiente que el modelo organizativo tradicional
Sanchez, Miquel - Reorganización de un área de Urgencias por niveles de urgen...ponencias_mihealth2012
La reorganización del área de urgencias del Hospital Clínic de Barcelona por niveles de urgencia en lugar de por especialidades redujo el tiempo de espera de los pacientes en un 22,8%, la estancia total en urgencias en un 11,1% y permitió atender un 7,6% más de pacientes diarios, todo ello con los mismos recursos humanos y espacios. Además, disminuyó la tasa de pacientes que abandonaban el área un 18,8% y las reclamaciones un 50%. La conclusión es que esta organización por niveles de urgencia es
Pascual, Josep - Network de atención a crónicos como práctica innovadora en a...ponencias_mihealth2012
Este documento describe el modelo de atención a pacientes crónicos de SARquavitae en Barcelona. El modelo incluye 49 centros residenciales para mayores, 10 centros de atención a discapacitados, 59 centros de día y 3 viviendas con servicios. Atienden a más de 200,000 personas al año con 12,200 empleados y 11,300 camas. El modelo se basa en la detección temprana, prevención, planificación anticipada y coordinación de recursos a través de una red para proporcionar una mejor calidad de vida y ser
Nuño, Roberto - Programa de estratificación poblacional en el País Vascoponencias_mihealth2012
Este documento describe el programa de estratificación poblacional implementado en el País Vasco. El programa clasifica a todos los ciudadanos basado en su riesgo de consumo de recursos de salud, identificando pacientes con enfermedades crónicas o en riesgo. El programa ha permitido mejorar la atención a pacientes crónicos de manera proactiva mediante programas diferenciados y la identificación de pacientes para intervenciones específicas. La estratificación complementa el criterio clínico y permite dirigir mejor los esfuerzos
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)MuskanShingari
Statistics- Statistics is the science of collecting, organizing, presenting, analyzing and interpreting numerical data to assist in making more effective decisions.
A statistics is a measure which is used to estimate the population parameter
Parameters-It is used to describe the properties of an entire population.
Examples-Measures of central tendency Dispersion, Variance, Standard Deviation (SD), Absolute Error, Mean Absolute Error (MAE), Eigen Value
Giloy in Ayurveda - Classical Categorization and SynonymsPlanet Ayurveda
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
How to Control Your Asthma Tips by gokuldas hospital.Gokuldas Hospital
Respiratory issues like asthma are the most sensitive issue that is affecting millions worldwide. It hampers the daily activities leaving the body tired and breathless.
The key to a good grip on asthma is proper knowledge and management strategies. Understanding the patient-specific symptoms and carving out an effective treatment likewise is the best way to keep asthma under control.
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
Denjoy, Nicole - The importante of innovative technologies in healthcare. COCIR’s viewpoint
1. The Industry Vision
Session S 1.4 Roundtable
The importance of innovative technologies in healthcare
COCIR’s viewpoint
Nicole Denjoy
COCIR Secretary General
25 May, Barcelona (Spain)
3. What is COCIR?
• It represents the industry leading
voice in Europe and beyond for:
• Medical Imaging,
• Health ICTs,
• Electromedical Industry.
June 17, 2009, page 3
5. COCIR National Trade Associations
Belgium Hungary Italy UK
Spain Netherlands Finland Netherlands
France Germany Sweden Turkey Germany
6. COCIR’s focus:
improve market access
• Provide COCIR’s members with competence towards policy
makers in Europe and outside
• Contribute to sustainability of healthcare systems through
integrated care approach
• Promote Research and Innovation as a key enabler for
economic growth
• Drive global regulatory convergence (registered once,
accepted everywhere)
• Optimise use of International standards
• Push for national and regional deployment (eHealth)
• Pro-active in Green Technology (Eco-Design)
9. Challenges
1 35 million deaths from chronic disease
2 60% of all deaths result from chronic
disease
3 Deaths from chronic disease will increase by 17% by 2015
2 17.5mm
Chronic disease deaths
Worldwide
7.6mm
4.1mm
1.4mm
Cardiovascular diseases Cancer Chronic Diabetes
respiratory disease
10. Societal health challenges
• An ageing population
• Growing prevalence of
chronic diseases
• A declining labour force
• Rising health care costs
June 17, 2009, page 10
11. Challenges for our Industry
• Highly regulated industry (under revision!)
• Lack of harmonisation in regulatory
framework globally & insufficient use of
international standards
• Various HTA & reimbursement systems in EU
• Still fragmented business in eHealth
• Lack of proper research funding &
insufficient use of structural funds in health
June 17, 2009, page 11
12. The industry cannot solve alone some key
challenges faced by innovations
• Investment and research are associated with high risks
Toward personalized medicine (niche markets) versus ROI
Innovative technologies to be integrated into a new, not yet defined
Healthcare System paradigm
• Low speed of adoption of new technologies with derived
clinical and economic benefits
New role of diagnostic & reimbursement issues
(biomarkers, companion diagnostic,…)
• Lack of standards to accelerate research and defragment
the market (globally)
Need for large clinical trials led by Clinical/Scientific experts groups
(e.g: AD taskforce, EORTC,…) supported by EC/EMA to validate new
medical practices to be reimbursed
June 17, 2009, page 12
14. Innovation in Medical Devices …
support improving outcomes in Cardiology
US Life Expectancy at Birth
1950-2000
80
75
70
Cancer Heart 65
1950 1960 1970 1980 1990 2000
Disease
Heart Cancer 5 out 7 years gained due
Disease to better heart care
Sources: NCHS,
Cutler 2006
“Around 70% of the survival improvement in heart attack
mortality is a result of changes in technology.”
Cutler & McClellan, 2001
June 17, 2009, page 14
15. Innovation in Medical Devices …
support improving outcomes in Oncology
Prostate cancer deaths Breast cancer deaths Colorectal cancer deaths
60 45 45
Per 100K females
Per 100K males
Per 100K pop
Deaths down 4.9%
40 30 30
Breast Male
Prostate
20 15 15
Female
Deaths down 4.1% Deaths down 3.5% Deaths down 4.5%
0 0 0
1975 2003 2008 1975 2003 2008 1975 2003 2008
• Prostate cancer mortality continues to fall: screening, PSA
• Breast cancer mortality decreased 3.5%: first drop in 20 years
• Colorectal cancer 5yr survival: 10% late stage; 90% early detection
“The decline in cancer has little to do with improvements in late stage
treatment...but more to do with screening, earlier detection and
treatment."
Prof. Gordon McVie, European Institute of Oncology, Milan
June 17, 2009, page 15
17. Medical Imaging innovations can turn
societal challenge into growth
• Yesterday
Patient stratification
Patient monitoring
• Tomorrow
Early diagnosis
Targeted treatment selection
Minimally invasive treatment
Treatment efficacy monitoring
Better quality & access to healthcare
Lower healthcare cost
INNOVATIONS
Quicker recovery of patients, quicker
return to daily activities
Economic Growth
(incl. jobs in EU for global markets)
June 17, 2009, page 17
18. Medical Imaging sector is strong in Europe…
• 3 of the global medical imaging industrial leaders are
headquartered in Europe, with strong R&D presence in
Europe
• Strong academic presence and Intellectual Property in
Europe can be leveraged for innovation (Patents registered
in 2010: 39% European, 26% US, 18% Japan and 5%
China and Korea)
June 17, 2009, page 18
19. Leverage the Power of Health ICT
Hospital
Government Polyclinic
• Healthcare IT and eHealth proven high clinical and
societal value
• Telehealth linking patients with care providers Home
Central
Pharmacy Patient’s
• IT infrastructure ensure that systems derive maximal EHR
value from medical technology (Cloud computing)
Laboratory
• IT connectivity through IHE (Integrating the Healthcare
Enterprise) improving quality and reducing cost
• More investment in eHealth best-practice clinical
pathways / patient’s mobility throughout Europe
June 17, 2009, page 19
20. Technology is advancing fast…..
Diagnostics Biotech & Genomics IT & bioengineering
• Faster, accurate imaging • Targeted therapy • eHealth/Telemedicine
• Molecular imaging • Proteomics/DNA • Mobile solutions
• Miniaturisation/portability • Biomarkers • BioSensors
• Point of Care diagnostics • Rapid screening tools • Computer Aided Diagnostics
• Therapy selection/monitor • Vaccine development • Patient monitoring
June 17, 2009, page 20
21. BUT…change is slow
Needpolicies that facilitate disease
management approaches:
o Focus on disease risk stratification, prevention & screening
programmes
o Encourage ‘best practice’ patient centric processes
o Health ICT solutions to drive quality, safety and efficiency,
and telemedicine
o Encourage more integrated care delivery
o Use of regulatory & procurement to accelerate uptake of
proven technologies
June 17, 2009, page 21
22. Two COCIR initiatives:
1. PPP in Research and Innovation
2. More effective PPP models: key best
practices on integrated care at
hospital level
June 17, 2009, page 22
23. 1. PPP for Research & Innovation
• Create an industry driven public-private partnership (PPP)
to accelerate Research and Innovation
• Together with Academics, Research Centers and Public
Authorities
• Join forces with other industry sectors (pharma, cosmetics,
etc….)
… in the context of “Horizon 2020” objectives of the
European Commission
The third objective, 'Societal challenges' will see €31.7
billion allocated to tackling the major issues affecting
the lives of European citizens, including Health,
demographic change and wellbeing (€8.6 billion – up
from €6.1 billion in FP7).
June 17, 2009, page 23
24. Benefits for European Commission
and Member States
• Better quality and lower cost healthcare for the most
important disease areas in EU and globally
Acceleration of efficient technology uptake, increasing ROI of
investments in healthcare technologies
• European Industrial and Scientific leadership
Prioritization of R&I in line with the industry needs to tackle
major global societal challenges
Better leverage of technology and clinical research outputs
PPP collaboration leads to better insights to jointly address future
problems
• Growth
Jobs creations derived from innovations commercialization
Indirect economic benefits of better management of chronic
diseases
June 17, 2009, page 24
25. 2. Hospital Of Today (HOT)
What you plan Today will remain optimal Tomorrow
A COCIR Initiative to maximize
investments at hospital level on
integrated solutions
June 17, 2009, page 25
26. Characteristics of a PPP
PPP has a number of characteristics which differentiates it from more traditional
forms of contracting between the public and private sectors:
1. Long term –Typically contracting period of 25 – 30 years. Over this period of time the private sector will
operate and maintain the facility.
2. Transfer of risk – certain financial, technical and operational risks are passed to the private sector for the
duration of a PPP contract.
3. Limited recourse finance – the financing within the Special Purpose Vehicle (SPV) is secured against the
project cash flows rather than the balance sheets of the SPV’s shareholders.
4. Payments over life of PPP contract– the Procuring Authority pays an annual Unitary Charge to the private
sector once service delivery has commenced (or in the case of toll funded projects payments are made by the
users of the service).
5. Private sector ownership – the private sector usually owns the asset for the duration of the contract. Upon
completion of the contract term, ownership of the asset can be transferred to the Procuring Authority.
6. Involves a range of partners – a number of private sector entities come together to form a consortium to
deliver the project.
26 June 17, 2009, page 26
27. Alternative Model PPP
De-couple Infrastructure from Technology
Government
Hospital
Managed Building
Service Concession
Technology
Consortium
Partner
• Construction Company
– Turnkey DBFMO model to provide infrastructure on 20 – 30 years lease basis
Design Build Finance Maintain Operate
• Equipment Technology Partnership
– Via a Managed Service based on Service Model and Service Level Agreement
– Providing flexibility in 10 – 15 years term
June 17, 2009, page 27
28. Valencia Region South
Integrated Patient Care System
- Full integrated patient care
- No waiting lists
- Patient has free choice to choose
hospital
- 600 € per capita, per year
Capitated payment
Property refund to
Valencia
Government
Public and free healthcare
services Controlled Project
June 17, 2009, page 28
30. Innovative technology will enable
a shift in care
• Focus on acute conditions Focus on acute & long term conditions
• Hospital centred Community centred
• Physician dependent Team based
• Episodic, reactive care Integrated preventive care
• Passive patient Knowledgeable patient
• Slow uptake of technology Localised integrated high tech solutions
• Budget silos Fund continuum of care
Hospital Community Home
clinic
Utilization
PRESENT FUTURE
High Acuity Low
June 17, 2009, page 30
31. Importance of prevention & personal
initiative for healthier and more active lifestyles
• Industry strongly supports government policies
and educational programs that encourage
individuals to make informed choices and take
personal initiatives for leading healthier and
more active lives
June 17, 2009, page 31
32. Collaborative partnership approach…
• Non-communicable diseases are multi-factorial
in nature, thus requiring a multi-stakeholder
and horizontal approach to ensure healthier
and informed life-styles
• Effective strategies must involve all levels of
government as well as all key stakeholders
June 17, 2009, page 32
33. Expectations to foster an innovation-
friendly environment in Europe
1.Establish a mechanism to ensure a robust evaluation of
innovations during the product-development cycle
2.Enable rapid access to market for innovative products
and services with added value
3.Adopt a clear strategy at EU level to support innovations
4.Access to further financing Research and Development
investments
5. Better leverage the use of Structural Funds for Health
June 17, 2009, page 33